Outlook Therapeutics stock last at USD 0.49 on October 16, 2026, 80.71 percent below high

Published on 10/17/2026 at 20:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Nasdaq compliance ends March 24, 2027. Outlook Therapeutics stock last at USD 0.49 on October 16, 2026, down 2.00 percent versus Nasdaq.

Listing deadline and earnings

The next Nasdaq compliance deadline is March 24, 2027.
Adjusted net loss reached USD 10.90 million in the third quarter of fiscal 2026.
Outlook Therapeutics stock last at USD 0.49 at 4:00 p.m. ET on October 16, 2026, 2.00 percent below the Nasdaq prior close.
Market capitalization stood at USD 118.9 million on October 16, 2026.

OTLK, US69012T3059, Illustration mit AI erstellt.

Outlook Therapeutics stock was last at USD 0.49 on October 16, 2026, or 80.71 percent below its 52-week high of USD 2.54. The price was 2.00 percent below the Nasdaq prior close on the last completed U.S. session.

The Nasdaq listing deadline matters more than the small daily move. On September 25, 2026, Outlook Therapeutics received a notice after its bid price had remained below USD 1.00 for 30 consecutive business days, according to the SEC filing.

Nasdaq deadline sets the calendar

The company has until March 24, 2027, to regain compliance by keeping its closing bid at or above USD 1.00 for at least ten consecutive business days. The notice did not immediately affect its Nasdaq Capital Market listing, but it placed a specific date on the company calendar.

Third-quarter losses remain material

Outlook Therapeutics reported an adjusted net loss of USD 10.90 million, or USD 0.09 per diluted share, in the third quarter of fiscal 2026, compared with an adjusted net loss of USD 15.80 million, or USD 0.44 per share, in the third quarter of fiscal 2025, according to Yahoo Finance on August 14, 2026. The adjusted comparison excludes non-cash and non-recurring items, including changes in warrant liability and promissory notes.

Outlook Therapeutics is commercializing LYTENAVA, an ophthalmic bevacizumab product for wet age-related macular degeneration. Its investor materials describe a U.S. launch strategy supported by distribution and commercial services from Cencora.

Price range keeps risk visible

The stock's 52-week range ran from USD 0.16 to USD 2.54 as of October 16, 2026. Its latest market capitalization was USD 118.9 million, while trading volume reached 3,087,236 shares against an average of 12,841,268 shares.

Comparison with peers

OTLK (Nasdaq, USD): minus 2.00 percent, market capitalization USD 118.9 million
KALA BIO (Nasdaq, USD): minus 1.20 percent, market capitalization USD 3.7 million
Harrow Health (Nasdaq, USD): minus 5.11 percent, market capitalization USD 1.0 billion

Outlook Therapeutics price and market context

The company remains in a commercial transition, while the Nasdaq deadline provides a dated test for the share price. Its current quotation is still 206.25 percent above the 52-week low, but 80.71 percent below the high.

Outlook Therapeutics was last at USD 0.49 at 4:00 p.m. ET on Nasdaq on October 16, 2026, 2.00 percent below the prior close.